Skip to main content
SpringerLink
Log in

Tierarzneimittel Zylexis® zur Krebsprävention und -therapie?

  • Was Patienten fragen
  • Published:
best practice onkologie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. DIMDI: Gebrauchinformation Zylexis®. http://portal.dimdi.de/amispb/doc/pei/Web/2603438-palde-20130301.pdf

  2. Einsatz vom Baypamun® beim Menschen. Bayerisches Ärzteblatt 11/2002, S. 618 http://www.blaek.de/presse/aerzteblatt/2002/ACF2CBB.pdf

Download references

Author information

Authors and Affiliations

  1. Deutsches Krebsforschungszentrum, Heidelberg, Deutschland

    A. Gaisser (Krebsinformationsdienst)

Authors
  1. A. Gaisser
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. Gaisser.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gaisser, A. Tierarzneimittel Zylexis® zur Krebsprävention und -therapie?. best practice onkologie 9, 53 (2014). https://doi.org/10.1007/s11654-014-0573-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11654-014-0573-3

Search

Navigation